Other glucose-lowering × lipids

TrialEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies.

Harold E BaysPubMed ↗Publisher ↗

What the trial testedas reported · 696 people

No range given

Reported higher lipids, no range given

+12.8percentage points

As reported

difference 12.8 %, no interval

No range given

Reported higher lipids, no range given

+3.30percentage points

As reported

difference 3.3 %, no interval

Two numbers in the abstract

the abstract, start to end

HCl (median treatment difference: +12.8%; P<.0001).

apo A-I (mean treatment difference: +3.3%; P<.0001), whereas the mean

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Lipids
12.8
Lipids
3.3
Other lipid agentsOther glucose-loweringLipids

Other glucose-lowering × lipidshelps?mixed

unlikelylikely
0.000.25 without it

Other lipid agents × lipidshelps?mixed

unlikelylikely
0.500.77 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

4 papers cite it

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
cites it
Full record →Abstract, authors, funding and every citing paper · PMID 21856592